Table 2.
Bone formation-related gene expression
| Treatment |
|||||
|---|---|---|---|---|---|
| Acute binge alcohol |
Chronic binge alcohol |
||||
| Common name | Description | % Control | P value | % Control | P value |
| Bone formation markers | |||||
| Alpl | Alkaline Phosphatase | 76.2 ± 4.3 | 0.015 | 83.2 ± 13.9 | 0.371 |
| Bglap | Osteocalcin | 30.8 ± 4.6 | 0.003 | 58.5 ± 13.6 | 0.081 |
| Bone morphogenetic proteins | |||||
| Bmp2 | Bone morphogenetic protein 2 | 90.2 ± 4.1 | 0.189 | 73.8 ± 11.9 | 0.046 |
| Bmpr2 | Bone morphogenic protein receptor II | 108.8 ± 6.2 | 0.205 | 55.7 ± 4.8 | 0.005 |
| Bmp4 | Bone morphogenetic protein 4 | 135.6 ± 29.2 | 0.055 | 56.8 ± 8.8 | 0.006 |
| Bmp5 | Bone morphogenetic protein 5 | 86.1 ± 5.5 | 0.095 | 56.1 ± 9.7 | 0.012 |
| Collagens | |||||
| Col1a2 | Pro-alpha-2(1) collagen | 64.1 ± 7.2 | 0.013 | 66.4 ± 7.9 | 0.006 |
| Col2a1 | Procollagen, type II, alpha 1 | 39.2 ± 7.0 | 0.011 | 46.3 ± 13.8 | 0.014 |
| Col4a1 | Procollagen, type IV, alpha 1 | 47.4 ± 5.1 | 0.004 | 53.7 ± 6.8 | 0.005 |
| Col4a2 | Procollagen, type IV, alpha 2 | 48.7 ± 4.2 | 0.003 | 53.6 ± 6.9 | 0.003 |
| Col4a3 bp | Procollagen, type IV, alpha 3 | 114.5 ± 5.3 | 0.102 | 72.6 ± 6.0 | 0.014 |
| Col4a4 | Procollagen, type IV, alpha 4 | 52.9 ± 4.4 | 0.004 | 87.7 ± 13.4 | 0.671 |
| Col5a1 | Collagen, type V, alpha 1 | 41.9 ± 3.7 | 0.003 | 36.9 ± 3.8 | 0.003 |
| Col6a2 | Procollagen, type VI, alpha 2 | 65.9 ± 5.3 | 0.015 | 61.9 ± 3.8 | 0.004 |
| Col9a1 | Procollagen, type IX, alpha 1 | 40.9 ± 9.8 | 0.020 | 56.3 ± 15.6 | 0.104 |
| Col9a3 | Procollagen, type IX, alpha 3 | 53.3 ± 8.3 | 0.029 | 57.0 ± 20.7 | 0.173 |
| Col10a1 | Collagen alpha 1 type X | 52.3 ± 11.7 | 0.047 | 61.4 ± 12.9 | 0.092 |
| Col15a1 | Procollagen, type XV | 81.4 ± 6.0 | 0.055 | 55.6 ± 7.3 | 0.004 |
| Col18a1 | Collagen, type XVIII, alpha 1 | 68.2 ± 4.3 | 0.015 | 65.5 ± 4.8 | 0.014 |
| Growth factors | |||||
| Fgfrl | Fibroblast growth factor receptor 1 | 72.2 ± 6.3 | 0.041 | 43.5 ± 4.6 | 0.003 |
| Fgfr2 | Fibroblast growth factor receptor 2 | 73.8 ± 5.2 | 0.015 | 52.2 ± 5.0 | 0.003 |
| Fgfr3 | Fibroblast growth factor receptor 3 | 69.0 ± 12.6 | 0.129 | 66.9 ± 3.4 | 0.026 |
| Igf1 | Insulin like growth factor 1 | 58.6 ± 3.6 | 0.003 | 60.0 ± 4.6 | 0.003 |
| Igf2 | Insulin like growth factor 2 | 85.2 ± 7.2 | 0.275 | 45.5 ± 6.5 | 0.003 |
| Pdgfa | Platelet derived growth factor, alpha | 78.3 ± 3.8 | 0.020 | 55.6 ± 6.5 | 0.003 |
| Tgfbl | Transforming growth factor, beta 1 | 64.5 ± 4.7 | 0.009 | 78.5 ± 4.5 | 0.026 |
| Tgfb2 | Transforming growth factor, beta 2 | 66.1 ± 10.8 | 0.034 | 46.0 ± 6.0 | 0.003 |
| Tgfb3 | Transforming growth factor, beta 3 | 56.3 ± 7.3 | 0.015 | 40.8 ± 3.6 | 0.003 |
| Vegf | Vascular endothelial growth factor | 82.5 ± 4.6 | 0.038 | 77.6 ± 6.9 | 0.026 |
| Vegfc | Vascular endothelial growth factor C | 146.1 ± 13.1 | 0.038 | 99.3 ± 23.6 | 0.933 |
| Other bone formation genes | |||||
| Sost | Sclerostin | 357.3 ± 71.3 | 0.013 | 107.2 ± 30.9 | 0.929 |
| Pthr1 | Parathyroid hormone receptor 1 | 59.1 ± 2.9 | 0.003 | 58.1 ± 5.6 | 0.003 |
Differential expression values and associated significance are shown for bone formation-associated gene expression. Each gene is listed by common name, description and expression value (±SEM) as a percentage of respective control for the following treatment groups: 1-week alcohol group, and 4-week alcohol group. Statistical comparisons were performed by Wilcoxon–Mann–Whitney nonparametric analysis with the Benjamini and Hochberg false discovery rate multiple testing correction